Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma

By Bedikian Agop   Johnson Marcella   Warneke Carla   Papadopoulos Nicholas   Kim Kevin   Hwu Wen-Jen   McIntyre Susan   Hwu Patrick  

Cancer Investigation, Vol. 26, Iss. 6, 2008-07 ,pp. : 624-633

Informa Healthcare

Access to resources Recommend Favorite

Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study

By Olivier Rixe   Jean-baptiste Meric   David Khayat   Claude Soubrane   Roger Mouawad  

Cytokines, Cellular & Molecular Therapy, Vol. 7, Iss. 4, 2002-12 ,pp. : 151-156

Informa Healthcare

Access to resources Recommend Favorite

Phase II Study of a Short Course of Weekly High-dose Cisplatin Combined with Long-term Oral Etoposide in Metastatic Malignant Melanoma

By Planting A.S.T.   van der Burg M.E.L.   Goey S.H.   Schellens J.H.M.   Vecht C.   de Boer-Dennert M.   Stoter G.   Verweij J.  

European Journal of Cancer, Vol. 32, Iss. 11, 1996-10 ,pp. : 2026-2028

Elsevier

Access to resources Recommend Favorite

A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma

By Mita Monica   Rowinsky Eric   Forero Leonardo   Eckhart S.   Izbicka Elzbieta   Weiss Geoffrey   Beeram Muralidhar   Mita Alain   Bono Johann   Tolcher Anthony   Hammond Lisa   Simmons Paul   Berg Kristin   Takimoto Chris   Patnaik Amita  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 2, 2007-02 ,pp. : 165-174

Springer Publishing Company

Access to resources Recommend Favorite

Metastatic melanoma: Is biochemotherapy the future?

By Alexandrescu Doru   Dutcher Janice   Wrnik Peter  

Medical Oncology, Vol. 22, Iss. 2, 2005-06 ,pp. : 101-111

Humana Press, Inc

Access to resources Recommend Favorite